Report Detail
Global Hemophilia A Drug Market Insights, Forecast to 2025
- RnM3036312 |
- 28 February, 2019 |
- Global |
- 126 Pages |
- QYResearch |
- Pharma & Healthcare
The global Hemophilia A Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hemophilia A Drug market based on company, product type, end user and key regions.
This report studies the global market size of Hemophilia A Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hemophilia A Drug in these regions.
This research report categorizes the global Hemophilia A Drug market by top players/brands, region, type and end user. This report also studies the global Hemophilia A Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Bayer AG
BioMarin Pharmaceutical Inc
Bioverativ Inc
Catalyst Biosciences Inc
Chugai Pharmaceutical Co Ltd
CSL Ltd
DBV Technologies SA
Dimension Therapeutics Inc
EpiVax Inc
Expression Therapeutics LLC
Green Cross Corp
Idogen AB
Immusoft Corp
LFB SA
mAbxience SA
Market size by Product
ATXF-8117
BAY-1093884
BIVV-001
BS-027125
Concizumab
CSL-689
Others
Market size by End User
Clinic
Hospital
ASCs
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Hemophilia A Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Hemophilia A Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Hemophilia A Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Hemophilia A Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Hemophilia A Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hemophilia A Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Hemophilia A Drug Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Hemophilia A Drug Market Size Growth Rate by Product
- 1.4.2 ATXF-8117
- 1.4.3 BAY-1093884
- 1.4.4 BIVV-001
- 1.4.5 BS-027125
- 1.4.6 Concizumab
- 1.4.7 CSL-689
- 1.4.8 Others
- 1.5 Market by End User
- 1.5.1 Global Hemophilia A Drug Market Size Growth Rate by End User
- 1.5.2 Clinic
- 1.5.3 Hospital
- 1.5.4 ASCs
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Hemophilia A Drug Market Size
- 2.1.1 Global Hemophilia A Drug Revenue 2014-2025
- 2.1.2 Global Hemophilia A Drug Sales 2014-2025
- 2.2 Hemophilia A Drug Growth Rate by Regions
- 2.2.1 Global Hemophilia A Drug Sales by Regions
- 2.2.2 Global Hemophilia A Drug Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Hemophilia A Drug Sales by Manufacturers
- 3.1.1 Hemophilia A Drug Sales by Manufacturers
- 3.1.2 Hemophilia A Drug Sales Market Share by Manufacturers
- 3.1.3 Global Hemophilia A Drug Market Concentration Ratio (CR5 and HHI)
- 3.2 Hemophilia A Drug Revenue by Manufacturers
- 3.2.1 Hemophilia A Drug Revenue by Manufacturers (2014-2019)
- 3.2.2 Hemophilia A Drug Revenue Share by Manufacturers (2014-2019)
- 3.3 Hemophilia A Drug Price by Manufacturers
- 3.4 Hemophilia A Drug Manufacturing Base Distribution, Product Types
- 3.4.1 Hemophilia A Drug Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Hemophilia A Drug Product Type
- 3.4.3 Date of International Manufacturers Enter into Hemophilia A Drug Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Hemophilia A Drug Sales by Product
- 4.2 Global Hemophilia A Drug Revenue by Product
- 4.3 Hemophilia A Drug Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Hemophilia A Drug Breakdown Data by End User
6 North America
- 6.1 North America Hemophilia A Drug by Countries
- 6.1.1 North America Hemophilia A Drug Sales by Countries
- 6.1.2 North America Hemophilia A Drug Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Hemophilia A Drug by Product
- 6.3 North America Hemophilia A Drug by End User
7 Europe
- 7.1 Europe Hemophilia A Drug by Countries
- 7.1.1 Europe Hemophilia A Drug Sales by Countries
- 7.1.2 Europe Hemophilia A Drug Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Hemophilia A Drug by Product
- 7.3 Europe Hemophilia A Drug by End User
8 Asia Pacific
- 8.1 Asia Pacific Hemophilia A Drug by Countries
- 8.1.1 Asia Pacific Hemophilia A Drug Sales by Countries
- 8.1.2 Asia Pacific Hemophilia A Drug Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Hemophilia A Drug by Product
- 8.3 Asia Pacific Hemophilia A Drug by End User
9 Central & South America
- 9.1 Central & South America Hemophilia A Drug by Countries
- 9.1.1 Central & South America Hemophilia A Drug Sales by Countries
- 9.1.2 Central & South America Hemophilia A Drug Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Hemophilia A Drug by Product
- 9.3 Central & South America Hemophilia A Drug by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Hemophilia A Drug by Countries
- 10.1.1 Middle East and Africa Hemophilia A Drug Sales by Countries
- 10.1.2 Middle East and Africa Hemophilia A Drug Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Hemophilia A Drug by Product
- 10.3 Middle East and Africa Hemophilia A Drug by End User
11 Company Profiles
- 11.1 Bayer AG
- 11.1.1 Bayer AG Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Bayer AG Hemophilia A Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Bayer AG Hemophilia A Drug Products Offered
- 11.1.5 Bayer AG Recent Development
- 11.2 BioMarin Pharmaceutical Inc
- 11.2.1 BioMarin Pharmaceutical Inc Company Details
- 11.2.2 Company Business Overview
- 11.2.3 BioMarin Pharmaceutical Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 BioMarin Pharmaceutical Inc Hemophilia A Drug Products Offered
- 11.2.5 BioMarin Pharmaceutical Inc Recent Development
- 11.3 Bioverativ Inc
- 11.3.1 Bioverativ Inc Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Bioverativ Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Bioverativ Inc Hemophilia A Drug Products Offered
- 11.3.5 Bioverativ Inc Recent Development
- 11.4 Catalyst Biosciences Inc
- 11.4.1 Catalyst Biosciences Inc Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Catalyst Biosciences Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Catalyst Biosciences Inc Hemophilia A Drug Products Offered
- 11.4.5 Catalyst Biosciences Inc Recent Development
- 11.5 Chugai Pharmaceutical Co Ltd
- 11.5.1 Chugai Pharmaceutical Co Ltd Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Products Offered
- 11.5.5 Chugai Pharmaceutical Co Ltd Recent Development
- 11.6 CSL Ltd
- 11.6.1 CSL Ltd Company Details
- 11.6.2 Company Business Overview
- 11.6.3 CSL Ltd Hemophilia A Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 CSL Ltd Hemophilia A Drug Products Offered
- 11.6.5 CSL Ltd Recent Development
- 11.7 DBV Technologies SA
- 11.7.1 DBV Technologies SA Company Details
- 11.7.2 Company Business Overview
- 11.7.3 DBV Technologies SA Hemophilia A Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 DBV Technologies SA Hemophilia A Drug Products Offered
- 11.7.5 DBV Technologies SA Recent Development
- 11.8 Dimension Therapeutics Inc
- 11.8.1 Dimension Therapeutics Inc Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Dimension Therapeutics Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Dimension Therapeutics Inc Hemophilia A Drug Products Offered
- 11.8.5 Dimension Therapeutics Inc Recent Development
- 11.9 EpiVax Inc
- 11.9.1 EpiVax Inc Company Details
- 11.9.2 Company Business Overview
- 11.9.3 EpiVax Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 EpiVax Inc Hemophilia A Drug Products Offered
- 11.9.5 EpiVax Inc Recent Development
- 11.10 Expression Therapeutics LLC
- 11.10.1 Expression Therapeutics LLC Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Expression Therapeutics LLC Hemophilia A Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Expression Therapeutics LLC Hemophilia A Drug Products Offered
- 11.10.5 Expression Therapeutics LLC Recent Development
- 11.11 Green Cross Corp
- 11.12 Idogen AB
- 11.13 Immusoft Corp
- 11.14 LFB SA
- 11.15 mAbxience SA
12 Future Forecast
- 12.1 Hemophilia A Drug Market Forecast by Regions
- 12.1.1 Global Hemophilia A Drug Sales Forecast by Regions 2019-2025
- 12.1.2 Global Hemophilia A Drug Revenue Forecast by Regions 2019-2025
- 12.2 Hemophilia A Drug Market Forecast by Product
- 12.2.1 Global Hemophilia A Drug Sales Forecast by Product 2019-2025
- 12.2.2 Global Hemophilia A Drug Revenue Forecast by Product 2019-2025
- 12.3 Hemophilia A Drug Market Forecast by End User
- 12.4 North America Hemophilia A Drug Forecast
- 12.5 Europe Hemophilia A Drug Forecast
- 12.6 Asia Pacific Hemophilia A Drug Forecast
- 12.7 Central & South America Hemophilia A Drug Forecast
- 12.8 Middle East and Africa Hemophilia A Drug Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Hemophilia A Drug Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Hemophilia A Drug . Industry analysis & Market Report on Hemophilia A Drug is a syndicated market report, published as Global Hemophilia A Drug Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Hemophilia A Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
